Adding oxaliplatin to fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy ( at the doses and intensities used in this trial ) significantly improved disease-free survival of patients with clinically staged cT@-@ or cN@-@ rectal cancer compared with our former fluorouracil-based combined modality regimen ( based on CAO/ARO/AIO -@ ) .